Top

Category: Mergers and Acquisitions


Mergers and Acquisitions

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

March 14, 2024

Via: World Pharma News

AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and […]


Mergers and Acquisitions

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

February 6, 2024

Via: Pharmaphorum

The €68-per-share cash offer has been approved by the boards of both companies, who say they expect it to be completed in the latter half of the year, subject to the usual regulatory approvals and other closing conditions. MorphoSys’ share […]


Mergers and Acquisitions

Biovian and 3P Biopharmaceuticals Combine to Form 3PBIOVIAN

February 5, 2024

Via: Biopharm International

Biovian, a contract development and manufacturing organization (CDMO), announced on Feb. 1, 2024 that it was combining with CDMO 3P Biopharmaceuticals to form 3PBIOVIAN under the two companies’ common shareholder, Keensight Capital. The new group, 3PBIOVIAN, will offer end-to-end development […]


Mergers and Acquisitions

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

January 23, 2024

Via: Pharmaphorum

France’s Sanofi – a major player in the rare disease category – is offering $30 per share for La Jolla, California-based Inhibrx, which had a closing price of just over $33 yesterday. The cash deal values the company at $1.7 […]


Mergers and Acquisitions

BridgeBio strikes drug royalty deal for cash infusion

January 18, 2024

Via: Biopharma Dive

BridgeBio Pharma has agreed to sell future royalties on an experimental rare disease drug in exchange for $500 million if the medicine, called acoramidis, receives Food and Drug Administration approval. The financing was extended by asset manager Blue Owl Capital […]


Mergers and Acquisitions

Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US

January 17, 2024

Via: Biopharm International

Taiwan’s largest pharmaceutical manufacturer, Bora Pharmaceuticals, has announced the approval by its Board of Directors for the acquisition of generics manufacturer, Upsher-Smith, which is based in Minnesota, USA, for a total of $210 million. According to a Jan. 16, 2024 […]


Mergers and Acquisitions

Körber and Franz Ziel Tighten Ties

December 28, 2023

Via: Biopharm International

There has been speculation around what manufacturing platforms, if any, can consolidate sufficient market share to dominate either specific operations (e.g., fill/finish) or more broadly, a full spectrum production suite of integrated operations. For the foreseeable future at least, it […]


Mergers and Acquisitions

AZ makes another cell therapy play with $1.2bn Gracell buy

December 26, 2023

Via: Pharmaphorum

The agreement is the latest in a series of acquisitions and licensing deals aimed at bolstering AZ’s position in cell therapy, an area where it has lagged behind other companies like Novartis, Bristol-Myers Squibb, and Gilead Sciences, and also continues […]


Mergers and Acquisitions

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

December 12, 2023

Via: Pharmaphorum

The $15-per-share deal is a 43% premium to Icosavax’s closing share price yesterday and values the company at around $1.1 billion, of which $800 million is payable near-term, with the remainder tied to certain future achievements. It is due to […]


Mergers and Acquisitions

Merck to buy private biotech Caraway in neuroscience deal

November 21, 2023

Via: Biopharma Dive

Caraway raised a small Series A round of $23 million in 2018, backed by several pharmaceutical venture arms, including Merck’s. At the time, the company went by the name of Rheostat Therapeutics. It rebranded to Caraway one year later, but […]


Mergers and Acquisitions

Triveni emerges from biotech merger with $92M for immune disease drugs

October 26, 2023

Via: Biopharma Dive

Triveni sees an opportunity to advance eczema treatment in a similar way to how psoriasis medicines have improved over the past decade, said Vishal Patel, the company’s CEO. In psoriasis, pills like Bristol Myers Squibb’s Sotyktu have joined mainstay biologics […]


Mergers and Acquisitions

Laronde, Senda Biosciences merge to create new Flagship company

October 19, 2023

Via: Biopharma Dive

Sail’s launch ends a difficult period for Laronde, a buzzy Flagship startup that brought in nearly $500 million to fund development of endless RNA-based medicines. Laronde drew investor interest for its work creating synthetic, circular versions of the nucleic acid […]


Mergers and Acquisitions

After summer slump, biotech M&A has a good week

October 10, 2023

Via: Biopharma Dive

This summer, large biotechnology deals took a vacation. In the three-month period from July through September, just six acquisitions worth at least $50 million were announced, according to data compiled by BioPharma Dive. The tally is half of what was […]


Mergers and Acquisitions

Sharp Acquires Berkshire Sterile Manufacturing

October 5, 2023

Via: Biopharm International

Sharp, a packaging and clinical trial supply services company, announced on Oct. 5, 2023 the acquisition of Berkshire Sterile Manufacturing (BSM), a contract development and manufacturing organization (CDMO) located in Massachusetts that offers clinical and commercial sterile injectable products. Sharp […]


Mergers and Acquisitions

Novo Nordisk acquires Embark Biotech in deal worth over €470m

August 31, 2023

Via: PMLiVE

The transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting obesity and other cardiometabolic diseases. In exchange, Embark Biotech will receive an upfront cash payment of €15m and will also be eligible to […]


Mergers and Acquisitions

Harmony Biosciences to Acquire Zynerba Pharmaceuticals

August 15, 2023

Via: Biopharm International

Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. 14, 2023, where Harmony will acquire all outstanding shares of Zynerba for a price of $1.1059 per share in cash, or $60 million in the aggregate, according to […]


Mergers and Acquisitions

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics

August 10, 2023

Via: Biopharm International

Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement on August 9, 2023, for the acquisition of Decibel by Regeneron at $4 per share of Decibel common stock payable in cash at closing. “We at Decibel are deeply committed to […]


Mergers and Acquisitions

iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein

August 4, 2023

Via: Biopharm International

On Aug. 1, 2023, US-based iTolerance, an early-stage regenerative medicine company, and Lithuania-based Northway Biotech, a contract development and manufacturing organization, announced that they have entered into an agreement for the manufacturing of Streptavidin-FasL (SA-FasL) fusion protein, an important component […]


Mergers and Acquisitions

Ayala Pharmaceuticals, Biosight Enter Definitive Merger Agreement

July 27, 2023

Via: Contract Pharma

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, and BioSight Ltd., a pharmaceutical company developing therapeutics for hematological malignancies and disorders, entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction. The combined […]


Mergers and Acquisitions

Novartis Acquires DTx Pharma in Deal Worth Up to $1 Billion

July 20, 2023

Via: Biopharm International

Novartis has acquired DTx Pharma, a US-based, preclinical-stage biotechnology company, for an upfront payment of $500 million plus additional payments of up to $500 million, dependent on the completion of pre-specified milestones, the companies announced in their respective July 17, […]